Mode of action of pertuzumab in combination with trastuzumab plus docetaxel therapy in a HER2-positive breast cancer xenograft model.

about

A Metabolomic Approach to Predict Breast Cancer Behavior and Chemotherapy Response.

P2860

Q52692110-4741550A-A147-4C3F-B190-EFA1987DC4D7

P2860

Mode of action of pertuzumab in combination with trastuzumab plus docetaxel therapy in a HER2-positive breast cancer xenograft model.

Item

http://www.wikidata.org/entity/Q41676872

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Mode of action of pertuzumab i ...... breast cancer xenograft model.

@en

type

Item

label

Mode of action of pertuzumab i ...... breast cancer xenograft model.

@en

prefLabel

Mode of action of pertuzumab i ...... breast cancer xenograft model.

@en

P1476

Mode of action of pertuzumab i ...... breast cancer xenograft model.

@en

P2093

Keigo Yorozu

http://www.w3.org/2001/XMLSchema#string

Naoki Harada

http://www.w3.org/2001/XMLSchema#string

Yoichiro Moriya

http://www.w3.org/2001/XMLSchema#string

Yoriko Yamashita-Kashima

http://www.w3.org/2001/XMLSchema#string

P2860

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015.

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells

Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.

ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency

P304

4197-4205

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/OL.2017.6679

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Sei Shu

P577

2017-07-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28959366

http://www.w3.org/2001/XMLSchema#string

P921

xenograft

P932

5607650

http://www.w3.org/2001/XMLSchema#string

Mode of action of pertuzumab in combination with trastuzumab plus docetaxel therapy in a HER2-positive breast cancer xenograft model.

about

P2860

P2860

Mode of action of pertuzumab in combination with trastuzumab plus docetaxel therapy in a HER2-positive breast cancer xenograft model.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932